The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis
Abstract
Objective: To determine the prognostic value of pulmonary function test (PFT) trends at 1 and 2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods: The prognostic significance of PFT trends at 1 year (n = 162) and 2 years (n = 140) was examined against 15‐year survival in patients with SSc‐associated ILD. PFT trends, expressed as continuous change and as categorical change in separate analyses, were examined against mortality in univariate and multivariate models. SSc‐associated ILD was defined at presentation as either limited lung fibrosis or extensive lung fibrosis, using the United Kingdom Raynaud's and Scleroderma Association severity staging system. Results: One‐year PFT trends were predictive of mortality only in patients with extensive lung fibrosis: categorical change in the forced vital capacity (FVC), alone or in combination with categorical change in the diffusing capacity for carbon monoxide (DL co), had greater prognostic significance than continuous change in the FVC or trends in other PFT variables. Taking into account both prognostic value and sensitivity to change, the optimal definition of progression for trial purposes was an FVC and DL co composite end point, consisting of either an FVC decline from baseline of ≥10% or an FVC decline of 5–9% in association with a DL co decline of ≥15%. At 2 years, gas transfer trends had the greatest prognostic significance, in the whole cohort and in those with limited lung fibrosis. However, in patients with extensive lung fibrosis, the above‐defined FVC and DL co composite end point was the strongest prognostic determinant. Larger changes in the FVC:DL co ratio than in the carbon monoxide transfer coefficient were required to achieve prognostic significance. Conclusion: Based on linkages to long‐term outcomes, these findings provide support for use of routine spirometry and gas transfer monitoring in patients with SSc‐associated ILD, with further evaluation of a composite FVC and DL co end point warranted for trial purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationCyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230
Self-citationEvidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
Coghlan, J. G., Denton, C. P., Grünig, E., Bonderman, D., Distler, O., Khanna, D., Müller-Ladner, U., Pope, J. E., Vonk, M. C., Doelberg, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203301 · Cited by 832
Self-citationBouros, D., Wells, A. U., Nicholson, A. G., Colby, T. V., Polychronopoulos, V., Pantelidis, P., Haslam, P. L., Vassilakis, D. A., Black, C. M., & du Bois, R. M. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2106012 · Cited by 820
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686
Self-citationFibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends
Latsi, P. I., du Bois, R. M., Nicholson, A. G., Colby, T. V., Bisirtzoglou, D., Nikolakopoulou, A., Veeraraghavan, S., Hansell, D. M., & Wells, A. U. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1245oc · Cited by 583
Self-citationPredicting Survival Across Chronic Interstitial Lung Disease
Ryerson, C. J., Vittinghoff, E., Ley, B., Lee, J. S., Mooney, J. J., Jones, K. D., Elicker, B. M., Wolters, P. J., Koth, L. L., King, T. E., et al. (2014) · Chest · doi:10.1378/chest.13-1474 · Cited by 558
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
Self-citation
Cited by
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Self-citationTocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Matucci-Cerinic, M., Distler, O., Shima, Y., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30318-0 · Cited by 662
Self-citationWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationSystemic sclerosis-associated interstitial lung disease
Perelas, A., Silver, R. M., Arrossi, A. V., & Highland, K. B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30480-1 · Cited by 422
George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30355-6 · Cited by 349
Self-citation
Metadata
- Authors
- Goh, N. S., Hoyles, R. K., Denton, C. P., Hansell, D. M., Renzoni, E. A., Maher, T. M., Nicholson, A. G., & Wells, A. U.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2017-07-18
- Volume
- 69
- Issue
- 8
- Pages
- 1670-1678
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2605548119
- Cited by
- 354
- References
- 31
- FWCI
- 21.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. https://app.cochat.ai/papers/10.1002/art.40130
- The paper
- Goh, N. S., Hoyles, R. K., Denton, C. P., Hansell, D. M., Renzoni, E. A., Maher, T. M., Nicholson, A. G., & Wells, A. U. (2017). Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis & Rheumatology. https://doi.org/10.1002/art.40130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.